Veru (VERU)
(Delayed Data from NSDQ)
$0.78 USD
-0.02 (-2.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.03%) 6:20 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Brokerage Reports
Veru Inc. [VERU]
Reports for Purchase
Showing records 61 - 80 ( 95 total )
Company: Veru Inc.
Industry: Medical - Products
Phase 2 COVID-19 Trial Enrolls First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
F2Q20 Financial Results; COVID-19 Trial Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Positive Phase 1b Preliminary Prostate Cancer Study Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Phase 2 Trial Doses First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 1Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 Hot Flashes Study Reports Positive Data; Reiterate Buy; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 4Q and Full-Year 2019 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 Hot Flashes Study Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 3Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
TADFIN 505(b)(2) NDA Submission Requirements Clarified; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Prostate Cancer Pipeline Strengthened with New Biologic Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 2Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Fiscal 1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Phase 1b/2 Prostate Cancer Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Tad-Fin Combo Tablet Delivers Positive Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
FY2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Financing Completed; Hot Flashes Trial Enrollment Starts; Reiterate Buy and Lowering Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Positive Pre-IND Meeting for VERU-111 in Prostate Cancer; Phase 1/2 Study Starts Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
South Africa Tender First Year Revenue Reaches $10.4M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
South Africa Female Condom Tender Awarded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R